The stock may react positively to the return to Q4 growth and improved margins, but traders should monitor whether the projected Dry Eye rebound and increased spending translate into sustained profitability. The path to cashflow breakeven remains key for long-term valuation.
Price Chart
Executive Summary
Sight Sciences reported Q4 and full-year 2025 results with mixed performance: Q4 revenue grew 7% to $20.4 million, driven by Glaucoma and Dry Eye segments, but full-year 2025 revenue declined 3% to $77.4 million. The company initiated 2026 guidance projecting revenue growth of 6%-14%, while increasing adjusted operating expenses due to strategic investments. Cash balance was $92.0 million as of year-end.
Key Financial Metrics
Key Facts
- Q4 2025 revenue: $20.4M (+7% YoY), driven by Interventional Glaucoma ($19.7M, +5%) and Interventional Dry Eye ($0.7M vs $0.3M in prior year)
- Full-year 2025 revenue: $77.4M (-3% YoY), with Glaucoma flat at $75.7M and Dry Eye down to $1.6M from $4.0M
- Net loss narrowed to $4.2M in Q4 2025 from $11.8M in Q4 2024; full-year net loss improved to $38.4M from $51.5M
- Gross margin stable at 87% in Q4, up to 86% for full year 2025 from 85% in 2024
- Cash and cash equivalents: $92.0M as of December 31, 2025, down from $120.4M in 2024; cash used in full year 2025 was $28.4M
- 2026 revenue guidance: $82M–$88M (6%–14% growth), including Dry Eye segment expected to rebound to $5M–$7M
- 2026 adjusted operating expenses guidance: $93M–$96M (+6%–9%), reflecting increased investment in commercial infrastructure
Financial Impact
Revenue expected to grow 6%-14% in 2026, but operating expenses to increase by 6%-9%; cash position remains strong at $92M despite higher cash usage
Risk Factors
- Interventional Dry Eye revenue collapsed in 2025 to $1.6M from $4.0M, raising concerns about commercial viability despite guidance for recovery
- Increased operating expenses in 2026 could pressure margins if revenue growth falls short of guidance
- Cash usage increased to $28.4M in 2025 from $17.8M in 2024, despite lower losses, suggesting working capital or investment pressures
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3249725 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | Press Release | $9.09 | awaiting T+5 | — | $9.02 (−0.77%) |
Oct 5, 2026 21d ago | Insider Cluster | $8.56 $8.39 | ▼ −1.99% | ▼ −1.85% | $9.02 (+5.37%) |
Aug 10, 2026 11w ago | 8-K | $7.70 $8.24 | ▲ +7.01% | ▲ +7.06% | $9.02 (+17.14%) |
Jul 6, 2026 15w ago | Insider Cluster | $5.35 $5.05 | ▲ +5.61% | ▲ +6.16% | $9.02 (−68.60%) |
Apr 23, 2026 26w ago | 8-K | $4.32 $3.97 | ▼ −8.10% | ▼ −9.58% | $9.02 (+108.80%) |
Apr 21, 2026 26w ago | Press Release | $4.27 $4.30 | ▲ +0.70% | ▲ +0.65% | $9.02 (+111.24%) |
Apr 1, 2026 29w ago | Insider Cluster | $3.66 $3.50 | ▲ +4.37% | ▲ +8.14% | $9.02 (−146.45%) |
Mar 4, 2026 33w ago | 8-K | $3.96 $3.62 | ▼ −8.59% | ▼ −6.35% | $9.02 (+127.78%) |
Mar 4, 2026 33w ago | Press Release | $3.96 $3.62 | ▼ −8.59% | ▼ −6.35% | $9.02 (+127.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers